<DOC>
	<DOCNO>NCT00952575</DOCNO>
	<brief_summary>This phase II study design demonstrate ability LFB-R593 effectively eliminate exogenously-administered RhD-positive red blood cell circulation RhD-negative individual , thereby prevent RhD-alloimmunisation .</brief_summary>
	<brief_title>Dose-finding Study LFB-R593 , A Monoclonal Anti-RhD Antibody , Healthy RhD Negative Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<criteria>Healthy RhDnegative volunteer Males definitively sterile female No prior sensitization RhD antigen Healthy RhDpositive volunteer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Prevention foeto-maternal allo-immunisation</keyword>
</DOC>